HAMILTON, Ontario, June 07, 2018 (GLOBE NEWSWIRE) -- CTT Pharmaceutical Holdings, Inc., (the “Company” or “CTT”) (OTC:CTTH), an innovative life sciences company with an extensive portfolio of IP in novel drug delivery systems, is pleased to announce that effective May 30, 2018, Cam Birge has been appointed President and a Director of the Company, replacing Dr. Pankaj Modi as President. Dr. Modi remains as Chief Executive Officer, Chief Science Officer and a Director of the Company.

“Mr. Birge arranged for and negotiated the recently announced partnership with Aurora Cannabis on behalf of CTT and its shareholders. We are delighted Mr. Birge has joined our management team and Board of Directors to help lead the Company through its next phase of development,” said Dr. Pankaj Modi CEO.

President

Mr. Birge has over 20 years of experience advising and working with public and private companies in Canada, the United States and Mexico. He also has over 20 years of experience in public and private education, including five years as Adjunct Professor of Business and twice elected Head of the Graduate Business Department of the Academic Council at United States International University, Mexico City campus.

He was the founder of Industrial Minerals Inc., the original owner of the Bissett Creek graphite project, and was responsible for the management change that led to the formation of Northern Graphite Corporation for which he is currently nominated as a Director. Mr. Birge previously was the Vice-President of the Trust for Sustainable Development and was instrumental in successfully negotiating the $3 billion Loreto Bay project with the Mexican federal government. He previously served with U.S. based public companies as CEO, CFO and as a Director. Mr. Birge is well connected both in capital markets and within the cannabis and other sectors.

“I am excited to have the opportunity to work with Dr. Modi and for the Board of Directors to further build shareholder value by expanding CTT’s patent portfolio and position the Company for future growth. I also look forward to working with our new partner, Aurora Cannabis, to further development of this technology for the benefit of so many people around the world,” said Mr. Birge.

CEO and Chief Science Officer

Dr Pankaj Modi, CEO and Chief Scientific Officer of CTT Pharma is an entrepreneurial clinician and research scientist and has been involved in novel delivery systems for the past several decades. His patented inventions range from spray formulae for the treatment of diabetes, which he licensed to Eli Lilly, and the topical delivery of botulinum toxins and other molecules that he licensed to Johnson and Johnson. He holds more than 25 US and Canadian patents and more than 280 world patents. Dr. Modi has obtained approval for 13 drugs over the past five years and currently has seven applications in process.

Dr. Modi is an M.D. in internal medicine. He holds a Ph.D. in chemistry, biochemistry and biomedical sciences, completed a post-doctoral fellowship in neuroscience and holds a M.S. in chemical engineering. Dr. Modi is an Adjunct Professor of Internal Medicine at several universities around the world and a Fellow with the Royal College of Medicine in the United Kingdom in addition to several other professional memberships in the United States and Brazil.

About CTT Pharmaceutical Holdings, Inc.

CTTH’s principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the “Wafer”). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its Wafer technology will be one of the first to gain use in major markets such as pain management.

The Oral Thin Film (Wafer) formulation is protected by several Canadian and U.S. patents.

CTTH’s oral fast dissolving drug delivery systems consist of wafers that dissolve without water and within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste; no smoke inhalation as is the case with cannabis; less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is also improved especially with those who have a fear of choking or difficulty swallowing, and/or are pediatric, geriatric or incapacitated.

For more information, please visit our website: www.cttpharmaceuticals.com

CTT’s common shares trade on the OTC market in the United States under the symbol “CTTH”.

Notice Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “estimates,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur, or be achieved.

Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including our future sales, income, and financial position. The forward-looking statements included in this news release are made as of the date of this news release and CTT not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities law.

For more information please contact:

Cam Birge

info@cttpharmaceuticals.com

(800) 516-1635